7-ethyl-10-hydroxycamptothecin (SN38), the active metabolite of irinotecan used in colorectal cancer therapy, is witnessing steady growth driven by increasing cancer prevalence and continuous advancements in oncology drug delivery systems. SN38 is widely recognized for its potent anticancer activity as a topoisomerase I inhibitor; however, its direct clinical application remains limited due to poor aqueous solubility, rapid degradation, and extremely low oral bioavailability.
Growing global incidence of colorectal cancer and other solid tumors continues to support research interest in SN38-based formulations. At the same time, pharmaceutical innovation is focusing on overcoming the compound’s physicochemical limitations through novel drug delivery approaches, particularly nanocarrier systems designed to improve oral absorption and systemic stability.
From a market structure perspective, SN38 operates within the oncology research and specialty pharmaceutical development segment. The compound is primarily used in research settings rather than as a standalone commercial drug, with significant R&D activity concentrated in North America, Europe, and Asia-Pacific regions.
Technological advancements in nanomedicine, including polymeric micelles, liposomal systems, and modified chitosan-based carriers, are playing a key role in enhancing SN38 delivery efficiency. These systems improve intestinal permeability, protect the drug from degradation, and enhance transport across biological barriers. Recent studies have demonstrated that amphiphilic polymeric micelles can significantly improve oral absorption and therapeutic performance of SN38. Despite strong research momentum, challenges remain, including formulation complexity, scalability limitations, and strict regulatory requirements for nanotechnology-based drug delivery systems. High development costs and the need for extensive clinical validation continue to slow down commercialization efforts.
Recent Industry Development
In January 2024, a significant research advancement was reported in the field of SN38 drug delivery, focusing on the development of self-assembled polymeric micelles based on deoxycholic acid–grafted N′-nonyl-trimethyl chitosan. This system was designed to improve the oral bioavailability and anticancer efficacy of SN38, addressing its long-standing limitations in clinical application. The study demonstrated that the engineered micelles significantly enhanced drug stability in gastrointestinal conditions, improved mucosal adhesion, and inhibited P-glycoprotein (P-gp) efflux mechanisms, which are known to reduce oral drug absorption. Additionally, the delivery system facilitated both paracellular and transcellular transport across the intestinal epithelium. Pharmacokinetic evaluations indicated a substantial increase in systemic exposure of SN38 following oral administration, along with improved in vivo antitumor efficacy compared to conventional formulations. These findings highlight the potential of advanced polymeric micelle systems in overcoming key barriers associated with SN38 delivery. This development reinforces growing scientific interest in nanocarrier-based chemotherapy strategies and suggests a promising pathway for improving oral cancer treatment options in the future.
